Table 1 Major Characteristics of GC patients with multiple clinical prognostic endpoints in TCGA
From: DNA methylation signatures associated with prognosis of gastric cancer
| Â | OS | DSS | PFI | DFI | |||
|---|---|---|---|---|---|---|---|
Training | Validation | Training | Validation | Training | Validation | Â | |
Total number, No | 191 | 190 | 186 | 186 | 192 | 191 | 247 |
Ethnicity, No. (%)a | |||||||
 Asian | 42 (22.0) | 41 (21.6) | 38 (20.4) | 42 (22.6) | 46 (24.0) | 37 (19.4) | 62 (25.1) |
 Black or African American | 9 (4.7) | 5 (2.6) | 6 (3.2) | 8 (4.3) | 10 (5.2) | 5 (2.6) | 7 (2.8) |
 White | 140 (73.3) | 144 (75.8) | 142 (76.3) | 136 (73.1) | 136 (70.8) | 149 (78.0) | 178 (72.1) |
Age, mean (SD) | 28.9 (10.7) | 29.2 (10.3) | 29.1 (10.9) | 28.7 (10.1) | 29.1 (10.5) | 29.0 (10.5) | 29. 3 (10.6) |
Gender, No. (%) | |||||||
 Male | 125 (65.4) | 126 (66.3) | 123 (66.1) | 121 (65.1) | 133 (69.3) | 120 (62.8) | 152 (61.5) |
 Female | 66 (34.6) | 64 (33.7) | 63 (33.9) | 65 (34.9) | 59 (30.7) | 64 (37.2) | 95 (38.5) |
Clinical stage, No. (%) | |||||||
 Stage I | 21 (11.0) | 27 (14.2) | 27 (14.5) | 20 (10.8) | 29 (15.1) | 20 (10.5) | 40 (16.2) |
 Stage II | 65 (34.0) | 56 (29.5) | 60 (32.3) | 58 (31.2) | 61 (31.8) | 60 (31.4) | 97 (39.3) |
 Stage III | 85 (44.5) | 85 (44.7) | 77 (41.4) | 88 (47.3) | 80 (41.7) | 91 (47.6) | 106 (42.9) |
 Stage IV | 16 (8.4) | 15 (7.9) | 14 (7.5) | 17 (9.1) | 18 (9.4) | 13 (6.8) | – |
 Unknown | 4 (2.1) | 7 (3.7) | 8 (4.3) | 3 (1.6) | 4 (2.1) | 7 (3.7) | 4 (1.6) |
Histologic grade, No. (%) | |||||||
 G1–2 | 67 (35.1) | 75 (39.5) | 76 (40.9) | 63 (33.9) | 73 (38.0) | 70 (36.6) | 91 (36.8) |
 G3 | 120 (62.8) | 110 (57.9) | 106 (57.0) | 118 (63.4) | 113 (58.9) | 118 (61.8) | 151 (61.1) |
 Unknown | 4 (2.1) | 5 (2.6) | 4 (2.2) | 5 (2.7) | 6 (3.1) | 3 (1.6) | 5 (2.0) |
Radiation therapy, No. (%) | |||||||
 Yes | 29 (15.2) | 21 (11.1) | 19 (10.2) | 31 (16.7) | 30 (15.6) | 22 (11.5) | 40 (16.2) |
 No | 127 (66.5) | 123 (64.7) | 129 (69.4) | 120 (64.5) | 119 (62.0) | 131 (68.6) | 187 (75.7) |
 Unknown | 35 (18.3) | 46 (24.2) | 38 (20.4) | 35 (18.8) | 43 (22.4) | 38 (19.9) | 20 (8.1) |
H. pylori infection, No. (%) | |||||||
 Yes | 11 (5.8) | 9 (4.7) | 9 (4.8) | 11 (5.9) | 7 (3.6) | 13 (6.8) | 15 (6.1) |
 No | 84 (44.0) | 80 (42.1) | 79 (42.5) | 80 (43.0) | 90 (46.9) | 75 (39.3) | 93 (37.7) |
 Unknown | 96 (50.3) | 101 (53.2) | 98 (52.7) | 95 (51.1) | 95 (49.5) | 103 (53.9) | 139 (56.3) |
Family history of GC, No. (%) | |||||||
 Yes | 11 (5.8) | 6 (3.2) | 8 (4.3) | 9 (4.8) | 8 (4.2) | 10 (5.2) | 11 (4.5) |
 No | 158 (82.7) | 157 (82.6) | 155 (83.3) | 154 (82.8) | 162 (84.4) | 153 (80.1) | 203 (82.2) |
 Unknown | 22 (11.5) | 27 (14.2) | 23 (12.4) | 23 (12.4) | 22 (11.5) | 28 (14.7) | 33 (13.4) |
Anatomic subdivision (%) | |||||||
 Antrum/Distal | 77 (40.3) | 64 (33.7) | 65 (34.9) | 71 (38.2) | 71 (37.0) | 70 (36.6) | 92 (37.2) |
 Cardia/Proximal | 24 (12.6) | 28 (14.7) | 34 (18.3) | 18 (9.7) | 27 (14.1) | 25 (13.1) | 28 (11.3) |
 Fundus/Body | 66 (34.6) | 72 (37.9) | 59 (31.7) | 76 (40.9) | 70 (36.5) | 68 (35.6) | 99 (40.1) |
 Gastroesophageal Junction | 19 (9.9) | 22 (11.6) | 21 (11.3) | 19 (10.2) | 19 (9.9) | 23 (12.0) | 23 (9.3) |
 Unknown | 5 (2.6) | 4 (2.1) | 7 (3.8) | 2 (1.1) | 5 (2.6) | 5 (2.6) | 5 (2.0) |
Pathologic T, No. (%) | |||||||
 T1–2 | 44 (23.0) | 48 (25.3) | 52 (28.0) | 38 (20.4) | 49 (25.5) | 44 (23.0) | 63 (25.5) |
 T3–4 | 147 (77.0) | 142 (74.7) | 134 (72.0) | 148 (79.6) | 143 (74.5) | 147 (77.0) | 184 (74.5) |
Pathologic N, No. (%) | |||||||
 N0–1 | 114 (59.7) | 103 (54.2) | 111 (59.7) | 99 (53.2) | 109 (56.8) | 109 (57.1) | 164 (66.4) |
 N2–3 | 74 (38.7) | 82 (43.2) | 70 (37.6) | 84 (45.2) | 81 (42.2) | 76 (39.8) | 78 (31.6) |
 Unknown | 3 (1.6) | 5 (2.6) | 5 (2.7) | 3 (1.6) | 2 (1.0) | 6 (3.1) | 5 (2.0) |
Pathologic M, No. (%) | |||||||
 M0 | 173 (90.6) | 169 (88.9) | 166 (89.2) | 169 (90.9) | 171 (89.1) | 172 (90.1) | 238 (96.4) |
 M1 | 9 (4.7) | 13 (6.8) | 12 (6.5) | 10 (5.4) | 11 (5.7) | 11 (5.8) | – |
 Unknown | 9 (4.7) | 8 (4.2) | 8 (4.3) | 7 (3.8) | 10 (5.2) | 8 (4.2) | 9 (3.6) |
Prognostic endpoints, No. (%) | |||||||
 Event | 77 (40.3) | 72 (37.9) | 55 (29.6) | 44 (23.7) | 77 (40.1) | 60 (31.4) | 46 (18.6) |
 Censored | 114 (59.7) | 118 (62.1) | 131 (70.4) | 142 (76.3) | 115 (59.9) | 131 (68.6) | 201 (81.4) |